Baker Bros. Raises Stake in Synageva BioPharma Corp (GEVA) Through Convention of Options

As a new form 4 filing with the Securities and Exchange Commission showed, Julian and Felix BakersBaker Bros Advisors, a fund focused on the biotechnology and healthcare companies, have revealed upping its long stake in Synageva BioPharma Corp (NASDAQ:GEVA). According to the filing, Baker Bros. have purchased close to 29,800 shares of the company at a price of $60.45 apiece. The price, which is much lower in comparison with the current stock price of Synageva BioPharma, was obtained following the conversion of the Non-Qualified Stock Options, held by the fund since 2005. In this way, currently, Baker Bros. owns almost 10.88 million shares of the company.

Synageva BioPharma

Earlier in April, Baker Bros has also converted options to purchase 56,000 shares of Synageva BioPharma Corp (NASDAQ:GEVA) at a price of $65.10 per share, held since 2007. In this way, Baker Bros. has solidified its position as one of the largest shareholders of the company.

The stock of Synageva BioPharma Corp (NASDAQ:GEVA) has surged by around 62% since the beginning of the year, and by 150% over the past year. The company has posted a significant net loss for the first quarter of the year, of $36.4 million, versus $14.5 million for the same period of the last year, while its revenue amounted to $1.6 million. According to a statement Synageva BioPharma Corp (NASDAQ:GEVA) is working on the development of its ARISE drug for Lysosomal Acid Lipase Deficiency treatment and plans to report top-line results from the Phase 3 trial during the third quarter of the year.

Other investors, among the funds we track, hold smaller positions in Synageva BioPharma. Jerome Pfund and Michael Sjostrom‘s Sectoral Asset Management owns 465,145 shares as of the end of March, down by 37% of the quarter. On the other hand, James E. Flynn‘s Deerfield Management and Donald Chiboucis‘ Columbus Circle Investors have initiated stakes in the company during the first quarter, reporting ownership of 317,700 shares and 186,300 shares of Synageva BioPharma Corp (NASDAQ:GEVA) respectively in their latest 13F filings.

Disclosure: none

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!